Skip to main
MAZE
MAZE logo

MAZE Stock Forecast & Price Target

MAZE Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Maze Therapeutics Inc. is advancing its clinical-stage programs with encouraging Phase 1 results for the MZE782 compound, which demonstrated significant pharmacodynamic activity, including a 42-fold increase in urinary phenylalanine and a benign hemodynamic mechanism without tubular injury. The positive data not only strengthens confidence in target engagement and mechanistic plausibility but also suggests the potential for MZE782 to carve out significant market share as a safer hemodynamic modulator in treating chronic kidney disease (CKD). With its innovative Compass platform underpinning the development of small-molecule precision medicines, Maze Therapeutics is well-positioned to harness human genetics in addressing renal and cardiovascular diseases, supporting a favorable outlook on its stock performance.

Bears say

The financial outlook for Maze Therapeutics Inc appears negative due to several critical risks associated with its pipeline products, MZE782 and MZE829. Key concerns include the potential failure of these candidates in clinical studies, the inability to secure regulatory approval in major markets like the US and EU, and challenges in achieving projected peak commercial revenues due to factors such as market size and pricing pressures. Additionally, systemic safety liabilities may constrain even potentially transformative therapies in the renal space, heightening uncertainty around the company's prospects.

MAZE has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Maze Therapeutics Inc (MAZE) Forecast

Analysts have given MAZE a Buy based on their latest research and market trends.

According to 7 analysts, MAZE has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Maze Therapeutics Inc (MAZE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.